

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-09** | Period of Report: **2013-01-08**  
SEC Accession No. [0001000096-13-000005](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

**Oncologix Tech Inc.**

CIK: [799694](#) | IRS No.: [861006416](#) | State of Incorporation: **NV** | Fiscal Year End: **0831**  
Type: **8-K** | Act: **34** | File No.: [000-15482](#) | Film No.: **13519703**  
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address

*P.O. BOX 8832*

*KENTWOOD MI 49518-8832*

Business Address

*P.O. BOX 8832*

*KENTWOOD MI 49518-8832*

*616-977-9933*

---

U.S. SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C.20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2013

**ONCOLOGIX TECH, INC.**

(Name of Small Business Issuer as Specified in Its Charter)

**Nevada**  
(State or other jurisdiction of  
incorporation or organization)

**0-15482**  
(Commission File Number)

**86-1006416**  
(I.R.S. Employer  
Identification No.)

P.O. Box 8832  
Grand Rapids, MI49518-8832  
(Address of principal executive offices)

(616) 977-9933  
(Issuer's telephone number)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Item 3.02. Unregistered Sales of Equity Securities

On January 8, 2013, the Company sold 2,000,000 shares of its common stock to three non-related accredited investors at \$0.01 per share. The sale resulted in gross proceeds to the Company of \$20,000. These shares are exempt from registration pursuant to SEC Regulation D.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: January 9, 2013

ONCOLOGIX TECH, INC.

By: /s/ Anthony Silverman  
Anthony Silverman, President

By: /s/ Michael A. Kramarz  
Michael A. Kramarz, Chief Financial Officer